EVLO Evelo Biosciences
- 0.001
- +0.000+25.00%
Evelo Biosciences News
Evelo Biosciences Analyst Ratings
Morgan Stanley Adjusts Evelo Biosciences' Price Target to $10 From $2, Keeps Equalweight Rating
Evelo Biosciences Analyst Ratings
Evelo Biosciences (EVLO) Gets a Hold From Morgan Stanley
Analysts Offer Insights on Healthcare Companies: Star Equity Holdings (STRR), Evelo Biosciences (EVLO) and 4D Molecular Therapeutics (FDMT)
Evelo Biosciences Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), DarioHealth (DRIO) and Evelo Biosciences (EVLO)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Align Tech (ALGN), Boston Scientific (BSX) and Evelo Biosciences (EVLO)
Evelo Biosciences Analyst Ratings
Chardan Downgrades Evelo Biosciences to Neutral From Buy, Cuts Price Target to $2.50 From $5
Evelo Biosciences Price Target Cut to $4.00/Share From $5.00 by Morgan Stanley
Evelo Biosciences Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley Cuts Price Target on Evelo Biosciences to $4 From $5, Maintains Equalweight Rating
Morgan Stanley Maintains Equal-Weight on Evelo Biosciences, Lowers Price Target to $4
Evelo Biosciences Analyst Ratings
Morgan Stanley Adjusts Evelo Biosciences' Price Target to $5 From $6, Maintains Equalweight Rating
Evelo Biosciences Analyst Ratings
Evelo Biosciences Price Target Cut to $5.00/Share From $6.00 by Morgan Stanley
Evelo Biosciences Is Maintained at Equal-Weight by Morgan Stanley
Evelo Biosciences Is Maintained at Buy by Chardan Capital
Analysis
Price Target
No Data
No Data